Symbols

ALT

Altimmune·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ALT

Altimmune, Inc.

A company that develops medical products to stimulate robust and durable immune responses for the prevention

Industry

Biological Technology

Established Date

04/25/2005

Listing Date

05/05/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.altimmune.com

Security Type

Common stock

Office address

910 Clopper Road, Suite 201S, Gaithersburg, MD 20878

Business

Introduction

Altimmune, Inc., was incorporated under the laws of the State of Delaware on April 25, 2005. The company is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver disease. The Company's lead product candidate, pemvidutide (formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (" MASH "), formerly known as non-alcoholic steatohepatitis (" NASH ").

Company Financials

EPS

ALT has released its 2025 Q4 earnings. EPS was reported at -0.27, versus the expected -0.25, missing expectations. The chart below visualizes how ALT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ALT has released its 2025 Q4 earnings report, with revenue of 26.00K, reflecting a YoY change of 420.00%, and net profit of -27.36M, showing a YoY change of -18.02%. The Sankey diagram below clearly presents ALT's revenue sources and cost distribution.